FDA approves Rx-to-OTC switch of head lice removal product

نویسندگان

چکیده

In October, FDA approved a prescription (Rx)-to-OTC conversion for the head lice removal product ivermectin (Sklice) 0.5% lotion. Health care experts and others hope OTC availability of will improve patients' accessibility to treatment. “I agree with change from OTC, as it [will] increase access this medication—no doctor visit needed or delay in treatment due lack available timely appointments [especially during pandemic],” said Anh Lam, PharmD, clinical pharmacist at Tufts Medical Center's Dermatology department Boston, MA. Below are some commonly asked questions about what Rx-to-OTC means. Ivermectin is topical pediculicide lotion indicated infestations patients ages 6 months older. It single-use straightforward easy-to-follow directions: Apply thoroughly dry scalp hair 10 minutes, then rinse out water. two studies, yielded higher proportion participants free live 14 days after compared vehicle control (76.1% 71.4% vs. 16.2% 18.9%, respectively). According “the medication generally well tolerated, minimal side effects such skin irritation, burning, conjunctivitis, eye irritation.” Since safe effective no need worry adherence combing nits—even though not ovicidal—it an appropriate switch. “Lice so difficult get rid because treatments only kill bugs—and they don't always all them—but do nits. All current require combing, proper true skill,” Melissa Balick, former business owner Hair Heroes Philadelphia. recent years, has grown resistant common like permethrin (Nix) synergized pyrethrins (Rid). Because have been widely many decades, used overused quite time, according William Ryan, BVSc, development Sklice. Retreatment by ill-informed also contributes inevitable resistance. Ironically, switch status brings up question affordability. “One my concerns price product,” Lam. Right now, she said, costs around $250 version GoodRx coupon. manufacturer retail pharmacies negotiate rebates make more affordable [for] patients,” Lam said. insurances cover products, high out-of-pocket cost would likely deter using ivermectin. Furthermore, product, contribute toward patient's deductible premium, ultimately defeating purpose approval that intended promote public health medication. pharmacists should counsel them aware part comprehensive program. Other important components removal, include washing hot water clothing, bedding, towels, other items touched patient, household members, close contacts. The American Academy Pediatrics recommends rinsing pediculicides off warm, rather than hot, sink minimize absorption unnecessary exposure. Especially children, avoid direct head-to-head contact prevent transmission. A single be three times if appears ineffective resistance improper use, CDC. “Switching [such as] pyrethrins, permethrin, malathion, benzyl alcohol, spinosad could next step,” Although oral option when therapies failed, monitor adverse systemic effects. recommended pregnant women children weighing less 15 kg safety data. Tabled 1Rx-to-OTC switches 2020Drug name (active ingredient)IndicationApproval dateSklice (ivermectin, 0.5%) lotionPediculicide infestations10/27/2020Pataday Once Daily Relief (olopatadine hydrochloride, 0.7%) ophthalmic solutionAntihistamine temporary relief itchy red eyes pollen, ragweed, grass, animal hair, dander7/13/2020Voltaren Arthritis Pain (diclofenac sodium, 1%) gelNSAID osteoarthritis pain joints, knees hands2/14/2020Pataday Twice 0.1%) dander2/14/2020Pataday 0.2%) solution Open table new tab Pharmacists encourage ask questions, especially prescribers bypassed use process, products. “I've had customers who told me got stuff, but hadn't worked,” Balick. “However, comes lice, people's personal experiences cannot really trusted understand little actually required lice. So, perhaps stuff did work, mistook dead nits sign infestation. Or, commonly, child simply again same place first time.”

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

FDA approves new drug to treat dementia.

Actavis and Adamas Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration has approved the New Drug Application for NamzaricTM for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric will be available in two dosage strengths: 28/10 mg (memantine extended release/donepezi...

متن کامل

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries

INTRODUCTION Triptans have been safely and effectively used in the management of migraine for more than fifteen years, and it seems reasonable to wonder what would be the economic impact of moving a specific triptan to OTC availability. The objective of this study was then to examine the economic impact of payer policies of a triptan Rx-to-OTC switch in six EU countries (France, UK, Spain, Ital...

متن کامل

The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health.

introducing me to the law and this topic, my family for their enduring support, and my editor, Benjamin Saul, for his guidance and careful eye.

متن کامل

FDA approves new drug to reduce risk of stroke.

Anew drug to reduce the risk of stroke has received approval from the US Food and Drug Administration. The new drug combines aspirin and dipyridamole into one pill to reduce the risk of stroke for patients who have already had transient ischemic attacks or ischemic strokes caused by blood clots in the brain. Approximately 500 000 people in the United States have strokes each year, and 150 000 d...

متن کامل

FDA approves kallikrein inhibitor to treat hereditary angioedema.

DOI 10.2146/news100005 Dyax Corp. on December 1 announced that FDA approved the marketing of the company’s ecallantide injection, or Kalbitor, for the treatment of acute attacks of hereditary angioedema in patients age 16 years or older. Ecallantide, the company said, binds to plasma kallikrein and blocks its binding site, resulting in less production of bradykinin, a vasodilator. According to ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Pharmacy Today

سال: 2021

ISSN: ['1042-0991', '2773-0735']

DOI: https://doi.org/10.1016/j.ptdy.2020.12.008